To summarize current knowledge regarding imaging in the renal cell carcinoma (RCC) patient pathway, emphasizing its critical role in improving patient outcomes and highlighting advances and key challenges.
Key Findings:
CT urography is the recommended first-line test for patients with unexplained visible haematuria, significantly impacting early diagnosis.
Ultrasound may be used for low-risk young patients with non-visible haematuria, but has low sensitivity for lesions < 1 cm, which can lead to missed diagnoses.
Up to 50% of renal cancer cases are detected incidentally, complicating the characterization of small renal masses and potentially delaying treatment.
The Bosniak classification system is crucial for assessing renal cysts, but has limitations in differentiating between categories IIF and III, which can affect management decisions.
Interpretation:
Imaging plays a vital role in the diagnosis, staging, and treatment response assessment of RCC, but challenges remain in accurately characterizing small renal masses and cysts, necessitating improved methodologies.
Limitations:
Lack of consensus on optimal imaging modalities for asymptomatic microscopic haematuria, leading to varied clinical practices.
Inter-observer disagreement in differentiating Bosniak IIF and III cysts, which can result in inconsistent management strategies.
Potential for overtreatment due to suboptimal effectiveness of the Bosniak classification, highlighting the need for refined diagnostic criteria.
Conclusion:
Advancements in imaging techniques are essential for improving diagnosis and management of renal tumors, but further research is urgently needed to address existing challenges.
